Zynerba Pharma CS (ZYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2017 | 12-2016 | 12-2015 | 12-2014 | 12-2013 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -32,012 | -23,389 | -12,551 | -5,670 | -637 |
| Depreciation Amortization | 94 | 75 | 26 | 27 | 49 |
| Accounts receivable | -370 | -3,257 | -357 | 35 | 102 |
| Accounts payable and accrued liabilities | 1,492 | 1,044 | 536 | 140 | 86 |
| Other Working Capital | 429 | -494 | 1,138 | 197 | 470 |
| Other Operating Activity | 4,524 | 5,582 | 1,421 | 1,731 | -188 |
| Operating Cash Flow | $-25,843 | $-20,438 | $-9,787 | $-3,541 | $-118 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -115 | -110 | -216 | -20 | -3 |
| Investing Cash Flow | $-115 | $-110 | $-216 | $-20 | $-3 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | -500 | N/A |
| Common Stock Issued | 57,728 | 10,001 | 42,186 | 1 | 38 |
| Other Financing Activity | -225 | 0 | 0 | 13,235 | 72 |
| Financing Cash Flow | $57,502 | $10,001 | $42,186 | $12,736 | $110 |
| Beginning Cash Position | 30,966 | 41,513 | 9,331 | 155 | 166 |
| End Cash Position | 62,510 | 30,966 | 41,513 | 9,331 | 155 |
| Net Cash Flow | $31,545 | $-10,547 | $32,182 | $9,176 | $-11 |
| Free Cash Flow | |||||
| Operating Cash Flow | -25,843 | -20,438 | -9,787 | -3,541 | -118 |
| Capital Expenditure | -115 | -110 | -216 | -20 | -3 |
| Free Cash Flow | -25,958 | -20,548 | -10,003 | -3,560 | -120 |